Vaccine: X最新文献

筛选
英文 中文
Assessment of the knowledge, attitude, and perception of the world's population towards monkeypox and its vaccines: A systematic review and descriptive analysis of cross-sectional studies 评估世界人口对猴痘及其疫苗的认识、态度和看法:横断面研究的系统回顾和描述性分析
IF 2.7
Vaccine: X Pub Date : 2024-08-02 DOI: 10.1016/j.jvacx.2024.100527
Mohammad Tanashat , Obieda Altobaishat , Abdulrahman Sharaf , Mostafa Hossam El Din Moawad , Mohammad Al-Jafari , Abdulqadir J. Nashwan
{"title":"Assessment of the knowledge, attitude, and perception of the world's population towards monkeypox and its vaccines: A systematic review and descriptive analysis of cross-sectional studies","authors":"Mohammad Tanashat ,&nbsp;Obieda Altobaishat ,&nbsp;Abdulrahman Sharaf ,&nbsp;Mostafa Hossam El Din Moawad ,&nbsp;Mohammad Al-Jafari ,&nbsp;Abdulqadir J. Nashwan","doi":"10.1016/j.jvacx.2024.100527","DOIUrl":"10.1016/j.jvacx.2024.100527","url":null,"abstract":"<div><h3>Background</h3><p>Prevention and treatment of the monkeypox virus (Mpox) remain challenging in areas where it is endemic. This systematic review and meta-analysis aimed to collect this information from various studies in one study to give a comprehensive view of people's opinions, fears, and behaviors about this virus.</p></div><div><h3>Methods</h3><p>We searched PubMed, Scopus, Web of Science, the Cochrane Library, and Google Scholar for descriptive cross-sectional study designs conducted in 2022 and 2023 addressing knowledge, attitude, perception, preparedness, willingness to get vaccinated, and practices against Mpox infection.</p></div><div><h3>Results</h3><p>Among the included studies, 16 studies assessed the level of knowledge of study participants regarding Mpox with a total of 9066 participants. Among them, 4222 (46.6 %) were reported to have good knowledge, and 4844 (53.4%) were reported to have poor knowledge about Mpox. Regarding willingness to get vaccinated against Mpox, 14 studies with a total of 10,696 participants were included. Among them, 7006 (65 %) were willing to get vaccinated while 3690 (35 %) weren’t willing to be vaccinated.</p></div><div><h3>Conclusion</h3><p>Knowledge about Mpox should be increased and awareness should be spread regarding the importance of preventive measures such as vaccination to protect the population from another COVID-19-like pandemic.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"20 ","pages":"Article 100527"},"PeriodicalIF":2.7,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224001001/pdfft?md5=7ed49664bd31d328604d9baf4a9393c5&pid=1-s2.0-S2590136224001001-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141953152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of different HA and NA gene combinations on the growth characteristics of the H3N8 influenza candidate vaccine virus 不同 HA 和 NA 基因组合对 H3N8 流感候选疫苗病毒生长特性的影响
IF 2.7
Vaccine: X Pub Date : 2024-08-01 DOI: 10.1016/j.jvacx.2024.100531
Liqi Liu, Zi Li, Jia Liu, Xiyan Li, Jianfang Zhou, Ning Xiao, Lei Yang, Dayan Wang
{"title":"Effects of different HA and NA gene combinations on the growth characteristics of the H3N8 influenza candidate vaccine virus","authors":"Liqi Liu,&nbsp;Zi Li,&nbsp;Jia Liu,&nbsp;Xiyan Li,&nbsp;Jianfang Zhou,&nbsp;Ning Xiao,&nbsp;Lei Yang,&nbsp;Dayan Wang","doi":"10.1016/j.jvacx.2024.100531","DOIUrl":"10.1016/j.jvacx.2024.100531","url":null,"abstract":"<div><p>Since 2022, three human cases of a novel H3N8 avian influenza virus infection have been reported in three provinces in China. Specific vaccines are important means of preparing for the potential influenza pandemic. Thus, H3N8 viruses [A/Henan/cnic410/2022 (HN410) and A/Changsha/1000/2022(CS1000)] were isolated from the infected patients as prototype viruses to develop candidate vaccine viruses (CVVs) using the reverse genetics (RG) technology. Five reassortant viruses with different HA and NA combinations were constructed based on the two viruses to get a high-yield and safe CVV. The results showed that all viruses had similar antigenicity but different growth characteristics. Reassortant viruses carrying NA from CS1000 exhibited better growth ability and NA enzyme activity than the ones carrying HN410 NA. Furthermore, the NA gene of CS1000 had one more potential N-glycosylation site at position 46 compared with HN410. The substitution of position 46 showed that adding or removing N-glycosylation sites to different reassortant viruses had different effects on growth ability. A reassortant virus carrying HN410 HA and CS1000 NA with high growth ability was selected as a CVV, which met the requirements for a CVV. These data suggest that different surface gene combinations and the presence or absence of potential N-glycosylation sites on position 46 in the NA gene affect the growth characteristics of H3N8 CVVs.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"19 ","pages":"Article 100531"},"PeriodicalIF":2.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224001049/pdfft?md5=f7cdf2466fc67d18eea671a1e35c55b6&pid=1-s2.0-S2590136224001049-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141839083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Post-introduction evaluation (PIE) of rotavirus vaccine in India 印度轮状病毒疫苗引入后评估 (PIE)
IF 2.7
Vaccine: X Pub Date : 2024-08-01 DOI: 10.1016/j.jvacx.2024.100526
Pawan Kumar , Arindam Ray , Amrita Kumari , Amanjot Kaur , Rhythm Hora , Kapil Singh , Rashmi Mehra , Seema S Koshal , Shipra Verma , Syed F. Quadri , Arup Deb Roy
{"title":"Post-introduction evaluation (PIE) of rotavirus vaccine in India","authors":"Pawan Kumar ,&nbsp;Arindam Ray ,&nbsp;Amrita Kumari ,&nbsp;Amanjot Kaur ,&nbsp;Rhythm Hora ,&nbsp;Kapil Singh ,&nbsp;Rashmi Mehra ,&nbsp;Seema S Koshal ,&nbsp;Shipra Verma ,&nbsp;Syed F. Quadri ,&nbsp;Arup Deb Roy","doi":"10.1016/j.jvacx.2024.100526","DOIUrl":"10.1016/j.jvacx.2024.100526","url":null,"abstract":"<div><h3>Background</h3><p>India became the first country in the WHO South-East Asia Region (SEAR) to introduce the rotavirus vaccine (RVV) in the Universal immunization programme (UIP) in 2016 with nationwide expansion by 2019. It was a landmark move to reduce the diarrheal disease burden in under-five children. To assess the implementation process of introduction of RVV, Post Introduction Evaluation (PIE) was conducted in March 2022.</p></div><div><h3>Methods</h3><p>The evaluation was conducted across 14 states, 28 districts and 28 health facilities to obtain a nationwide geographical inclusion. Stakeholders involved in program decision-making, planning, training, vaccine delivery, logistics, and communication from all levels (National, state, district, health facility, health worker, caregiver) were interviewed using standardized data collection tool for PIE (adapted from the standard WHO PIE questionnaire) and scripted on a digital tool.</p></div><div><h3>Results</h3><p>A total of 260 interviews were conducted. Political willingness, well-planned preparedness activities, securing vaccines timely, strong supply chain monitoring, availability of domestic RVV products, quality trainings and intense communication activities were the key factors identified for the successful RVV introduction. Key activities during the introduction included cold chain space assessment, trainings of healthcare workforce, dissemination of job aids, updation of recording &amp; reporting formats and strengthening of AEFI surveillance. Lack of community awareness for immunization in a few areas, fear of AEFI amongst some caregivers and local issues with Alternate Vaccine Delivery (AVD) were some reported challenges in achieving high coverage for RVV.</p></div><div><h3>Conclusions</h3><p>Overall, the nationwide roll-out of RVV was smooth and the vaccine has been well-accepted in the community. The assessment emphasizes on having a well-strategized operational and communication planning, which is very crucial for any new vaccine introduction.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"19 ","pages":"Article 100526"},"PeriodicalIF":2.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224000998/pdfft?md5=333ec60cdd772a04b8519154e93a1ca3&pid=1-s2.0-S2590136224000998-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141840668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors influencing parental COVID-19 vaccination willingness for children in Japan 影响日本父母为儿童接种 COVID-19 疫苗意愿的因素
IF 2.7
Vaccine: X Pub Date : 2024-08-01 DOI: 10.1016/j.jvacx.2024.100528
Mami Ueta , Alton Cao , Michio Murakami , Hana Tomoi , Stuart Gilmour , Keiko Maruyama-Sakurai , Yoshihiro Takayama , Yoshitake Takebayashi , Masahiro Hashizume , Rauniyar Santosh Kumar , Hiroyuki Kunishima , Wataru Naito , Tetsuo Yasutaka , Satoshi Kaneko , Hiroaki Miyata , Shuhei Nomura
{"title":"Factors influencing parental COVID-19 vaccination willingness for children in Japan","authors":"Mami Ueta ,&nbsp;Alton Cao ,&nbsp;Michio Murakami ,&nbsp;Hana Tomoi ,&nbsp;Stuart Gilmour ,&nbsp;Keiko Maruyama-Sakurai ,&nbsp;Yoshihiro Takayama ,&nbsp;Yoshitake Takebayashi ,&nbsp;Masahiro Hashizume ,&nbsp;Rauniyar Santosh Kumar ,&nbsp;Hiroyuki Kunishima ,&nbsp;Wataru Naito ,&nbsp;Tetsuo Yasutaka ,&nbsp;Satoshi Kaneko ,&nbsp;Hiroaki Miyata ,&nbsp;Shuhei Nomura","doi":"10.1016/j.jvacx.2024.100528","DOIUrl":"10.1016/j.jvacx.2024.100528","url":null,"abstract":"<div><h3>Objectives</h3><p>This study aims to investigate the factors influencing parental willingness in COVID-19 vaccination for children in Japan in light of the introduction of pediatric vaccines.</p></div><div><h3>Methods</h3><p>An online survey was conducted in February 2022, coinciding with the imminent start of pediatric COVID-19 vaccinations in Japan. It assessed attitudes toward vaccine uptake and included questions about health-related attributes, psychological considerations, and sources of COVID-19 information. Data from 2,419 respondents who had children under the age of 12 were analyzed using multinomial logistic regression to identify factors associated with parental willingness towards COVID-19 vaccination for children. The outcomes were “agree” (in favor of vaccination), “not sure” (undecided), with “disagree” (against vaccination) as the reference category.</p></div><div><h3>Results</h3><p>Among participants supportive of vaccination (“agree” compared to the “disagree” reference), salient determinants included: gender (Men in reference to women: odds ratio [OR] 1.54; 95 % confidence interval [CI] 1.11–2.15), highest educational level (Junior College/Vocational in reference to under high school: OR 0.61; 95 % CI 0.40–0.93, Bachelor’s /Master’s/Doctoral degree in reference to under high school: OR 0.59; 95 % CI 0.42–0.84), perception of benefits of COVID-19 vaccination (Significant in reference to Insignificant: OR 2.04; 95 % CI 1.26–3.28), perception of risks of COVID-19 vaccination (Significant in reference to Insignificant: OR 0.28; 95 % CI 0.19–0.42, Neutral in reference to Insignificant: OR 0.48; 95 % CI 0.33–0.71), the number of referenced information sources utilized for COVID-19 was associated with attitudes towards children’s vaccination (OR 1.02; 95 % CI 1.00–1.04).</p></div><div><h3>Conclusion</h3><p>The study highlights the multifaceted factors influencing parents’ COVID-19 vaccination attitudes for their children, encompassing socioeconomic, health, psychological, and informational aspects. Factors like cautious information gathering, vaccine concerns and diverse referenced information sources impact willingness. To facilitate informed decision-making, essential measures include government risk communication, widespread vaccine information dissemination, and enhancing parents’ health information accessibility and evaluation skills are important.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"19 ","pages":"Article 100528"},"PeriodicalIF":2.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224001013/pdfft?md5=36250064aeac5fa28b34166c7c402200&pid=1-s2.0-S2590136224001013-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141844901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations of mothers’ decisional conflicts and satisfaction with governmental health promotion materials with their daughters’ HPV vaccination uptake in China: A cross-sectional survey 在中国,母亲的决策冲突和对政府健康宣传材料的满意度与女儿接种HPV疫苗的相关性:横断面调查
IF 2.7
Vaccine: X Pub Date : 2024-08-01 DOI: 10.1016/j.jvacx.2024.100529
Zian Lin , Siyu Chen , Lixian Su , He Cao , Hongbiao Chen , Yuan Fang , Xue Liang , Jianan Chen , Biyun Luo , Chuanan Wu , Zixin Wang
{"title":"Associations of mothers’ decisional conflicts and satisfaction with governmental health promotion materials with their daughters’ HPV vaccination uptake in China: A cross-sectional survey","authors":"Zian Lin ,&nbsp;Siyu Chen ,&nbsp;Lixian Su ,&nbsp;He Cao ,&nbsp;Hongbiao Chen ,&nbsp;Yuan Fang ,&nbsp;Xue Liang ,&nbsp;Jianan Chen ,&nbsp;Biyun Luo ,&nbsp;Chuanan Wu ,&nbsp;Zixin Wang","doi":"10.1016/j.jvacx.2024.100529","DOIUrl":"10.1016/j.jvacx.2024.100529","url":null,"abstract":"<div><h3>Background</h3><p>China started to implement the HPV vaccination program for females in 2016. This study investigated associations between mothers’ decisional conflicts, satisfaction with governmental health promotion materials, and their daughters’ HPV vaccination uptake.</p></div><div><h3>Methods</h3><p>A cross-sectional online survey was conducted between July and October 2023 among mothers of girls aged 9–17 years in Shenzhen, China. Participants were mothers having a daughter aged 9–17 years at the survey date and a smartphone with internet access. About 3 % of all primary and secondary schools in Shenzhen were randomly selected by the research team (11 primary schools and 13 secondary schools). Teachers at the selected schools invited mothers of female students aged 9–17 years to complete an anonymous online questionnaire. Multivariate logistic regression was fitted.</p></div><div><h3>Results</h3><p>Among 11,728 mothers who completed the survey, 18.9% of their index daughters received at least one dose of HPV vaccination. In multivariate analysis, less decisional conflict about the choice of HPV vaccines for their daughters (AOR: 1.07, 95%CI: 1.05, 1.10), more satisfaction with the government’s health promotional materials related to HPV vaccines (AOR: 1.15, 95%CI: 1.12, 1.19), receiving more cue to action from significant others (AOR: 1.23, 95%CI: 1.19, 1.27), and perceived higher self-efficacy related to HPV vaccines (AOR: 1.79, 95%CI: 1.67, 1.92) were associated with a higher uptake of HPV vaccines. Perceived susceptibility to HPV (AOR: 0.79, 95%CI: 0.74, 0.85), perceived barriers to having the index daughter receive HPV vaccines (AOR: 0.82, 95%CI: 0.80, 0.84), and mothers who were hesitant to receive HPV vaccination (AOR: 0.75, 95%CI: 0.68, 0.84) were associated with a lower uptake.</p></div><div><h3>Conclusion</h3><p>HPV vaccination uptake was low among girls in China. Future health promotion should address mothers’ decisional conflicts about the choice of HPV vaccines for their daughters and improve the health promotional materials. School-based HPV vaccination programs might be useful.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"19 ","pages":"Article 100529"},"PeriodicalIF":2.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224001025/pdfft?md5=7c5f5dfb30a197f7937dab0e184a474a&pid=1-s2.0-S2590136224001025-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141846359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Knowledge of caregivers regarding pneumococcal diseases and pneumococcal conjugate vaccine (PCV): A cross sectional study at a district in India 护理人员对肺炎球菌疾病和肺炎球菌结合疫苗 (PCV) 的了解:印度一个地区的横断面研究
IF 2.7
Vaccine: X Pub Date : 2024-08-01 DOI: 10.1016/j.jvacx.2024.100532
Jayanta Majumder , Arindam Ray , Pradeep Haldar , Arup Deb Roy , Debasis Roy , Nitai Chandra Mandal , Tanmay Mahapatra
{"title":"Knowledge of caregivers regarding pneumococcal diseases and pneumococcal conjugate vaccine (PCV): A cross sectional study at a district in India","authors":"Jayanta Majumder ,&nbsp;Arindam Ray ,&nbsp;Pradeep Haldar ,&nbsp;Arup Deb Roy ,&nbsp;Debasis Roy ,&nbsp;Nitai Chandra Mandal ,&nbsp;Tanmay Mahapatra","doi":"10.1016/j.jvacx.2024.100532","DOIUrl":"10.1016/j.jvacx.2024.100532","url":null,"abstract":"<div><h3>Background</h3><p>To reduce burden of pneumonia, India has introduced Pneumococcal Conjugate vaccine (PCV) in routine immunization programme. The state of West Bengal, India introduced PCV in 2021. Uptake of new vaccines depends a lot on knowledge of caregivers on the disease and vaccine<strong>.</strong> This study aimed to assess the knowledge of caregivers regarding pneumococcal diseases and PCV. The study will inform programme managers to develop a comprehensive demand generation strategy for improving uptake of PCV and other new vaccines.</p></div><div><h3>Methods</h3><p>It is an observational, cross-sectional study using a predesigned, pretested and structured questionnaire conducted among 353 caregivers of children who has received at least one dose of PCV. The children were aged between 6 weeks to 20 months, residing in rural and urban areas of Howrah district of West Bengal. Sample size was calculated considering 95 % confidence interval and 5 % margin of error.</p></div><div><h3>Results</h3><p>Results are analysed taking into consideration rural/urban divide, socioeconomic status and other factors influencing vaccine uptake. Study findings suggest lack of knowledge of caregivers regarding pneumococcal diseases and PCV. Most of respondents have no idea about any other pneumococcal diseases apart from pneumonia. More than 40 % does not know about what causes pneumonia and more than 47 % does not know how to prevent pneumonia. They also have poor knowledge about injection site, number of doses, schedule and when to start PCV.</p></div><div><h3>Conclusions</h3><p>Limited knowledge among caregivers may cause negative impact on vaccine coverage and jeopardise the goal of government to reduce morbidity and mortality due to pneumonia.</p><p>The study findings suggest that there is dearth of knowledge regarding pneumococcal diseases and PCV among caregivers. Therefore the policy makers need to develop a comprehensive plan for awareness generation for improving PCV uptake and strategy developed for this purpose can be implemented in future new vaccine introduction also.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"19 ","pages":"Article 100532"},"PeriodicalIF":2.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224001050/pdfft?md5=41a687e4e9e02fc49f11f3cf8579e939&pid=1-s2.0-S2590136224001050-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141846775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of anti-phospholipid antibody titers before and after SARS-CoV-2 mRNA vaccination in hospital staff 医院工作人员接种 SARS-CoV-2 mRNA 疫苗前后抗磷脂抗体滴度的比较
IF 2.7
Vaccine: X Pub Date : 2024-07-30 DOI: 10.1016/j.jvacx.2024.100539
Michi Hisano , Naho Morisaki , Makiko Sampei , Erika Obikane , Koushi Yamaguchi
{"title":"Comparison of anti-phospholipid antibody titers before and after SARS-CoV-2 mRNA vaccination in hospital staff","authors":"Michi Hisano ,&nbsp;Naho Morisaki ,&nbsp;Makiko Sampei ,&nbsp;Erika Obikane ,&nbsp;Koushi Yamaguchi","doi":"10.1016/j.jvacx.2024.100539","DOIUrl":"10.1016/j.jvacx.2024.100539","url":null,"abstract":"<div><p>Multiple concerning reports have emerged of cardiovascular complications, particularly thrombosis, following mRNA vaccination against the SARS-CoV-2 pathogen. The presence of serologically persistent anti-phospholipid antibodies is a characteristic of antiphospholipid syndrome, which presents with clinical manifestations including thrombosis or pregnancy morbidity. Anti-SARS-CoV-2 mRNA vaccines pose a theoretical risk of cross-reactivity between the SARS-CoV-2 spike protein and phospholipids in host tissues. In this study, serum anti-phospholipid antibody titers before and after SARS-CoV-2 mRNA vaccination were compared among 184 hospital staff members. Although no significant differences were found in terms of antibody titers targeting cardiolipin and β2-glycoprotein I, post-vaccination antibody titers targeting phosphatidylethanolamine were found to be significantly increased compared to pre-vaccination levels (<em>p</em> = 0.008). Anti-phosphatidylethanolamine antibodies are the most common anti-phospholipid antibodies detected in patients with recurrent miscarriages at &lt; 10 weeks of gestation. However, the association between vaccination and these types of adverse events remains unknown, thus warranting further investigation.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"20 ","pages":"Article 100539"},"PeriodicalIF":2.7,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224001128/pdfft?md5=de3f22c2f043423e258767d7bb1a7fa4&pid=1-s2.0-S2590136224001128-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141961469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and antibody responses of Omicron BA.4/5 bivalent booster vaccine among hybrid immunity with diverse vaccination histories: A cohort study 具有不同疫苗接种史的混合免疫接种Omicron BA.4/5二价加强免疫疫苗的安全性和抗体反应:一项队列研究
IF 2.7
Vaccine: X Pub Date : 2024-07-28 DOI: 10.1016/j.jvacx.2024.100538
Sitthichai Kanokudom , Jira Chansaenroj , Nungruthai Suntronwong , Lakkhana Wongsrisang , Ratchadawan Aeemjinda , Preeyaporn Vichaiwattana , Thaksaporn Thatsanathorn , Warangkana Chantima , Pattarakul Pakchotanon , Thaneeya Duangchinda , Natthinee Sudhinaraset , Sittisak Honsawek , Yong Poovorawan
{"title":"Safety and antibody responses of Omicron BA.4/5 bivalent booster vaccine among hybrid immunity with diverse vaccination histories: A cohort study","authors":"Sitthichai Kanokudom ,&nbsp;Jira Chansaenroj ,&nbsp;Nungruthai Suntronwong ,&nbsp;Lakkhana Wongsrisang ,&nbsp;Ratchadawan Aeemjinda ,&nbsp;Preeyaporn Vichaiwattana ,&nbsp;Thaksaporn Thatsanathorn ,&nbsp;Warangkana Chantima ,&nbsp;Pattarakul Pakchotanon ,&nbsp;Thaneeya Duangchinda ,&nbsp;Natthinee Sudhinaraset ,&nbsp;Sittisak Honsawek ,&nbsp;Yong Poovorawan","doi":"10.1016/j.jvacx.2024.100538","DOIUrl":"10.1016/j.jvacx.2024.100538","url":null,"abstract":"<div><p>This cohort study, conducted between July and August 2023, evaluated the adverse events (AEs) and immune response to a bivalent mRNA-1273.222 (containing sequences of the original Wuhan-H1 strain and the Omicron BA.4/5 variant) booster vaccine in 122 participants. The study included individuals with diverse vaccination histories, and their responses were assessed based on anti-receptor binding domain (RBD) IgG levels and neutralizing antibodies against the wild-type, Omicron BA.5, and XBB.1.16 variants. Following administration of the BA.4/5 bivalent vaccine, AEs were generally mild to moderate and well-tolerated within a few days. There were no reports of vomiting and no serious AEs or death. The findings demonstrated robust immune responses, with significant increases in anti-RBD IgG levels, particularly in groups that had received 3 –6 doses before the booster dose. The BA.4/5 bivalent booster effectively induced neutralizing antibodies against the vaccine strains, providing robust neutralization, including the XBB.1.16 strain. The study also highlighted that individuals with hybrid immunity, especially those assumed infected with the BA.5 strain or who had been infected twice, showed higher levels of robust neutralizing activity against Omicron XBB.1.16. Overall, these results indicate that the BA.4/5 bivalent booster vaccines can induce potent and good antibody responses in emerging Omicron subvariants, supporting its efficacy as a booster in individuals with diverse vaccination histories.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"20 ","pages":"Article 100538"},"PeriodicalIF":2.7,"publicationDate":"2024-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224001116/pdfft?md5=279b83a03fe8e2e3b75f37d89c1b39c0&pid=1-s2.0-S2590136224001116-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141851969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing vaccine hesitancy and vaccine literacy among the European prison population and staff: A multicentre observational study 评估欧洲监狱服刑人员和工作人员对疫苗的犹豫态度和疫苗知识:多中心观察研究
IF 2.7
Vaccine: X Pub Date : 2024-07-27 DOI: 10.1016/j.jvacx.2024.100537
D. Petri , M. Fornili , E. De Vita , M.A. Malanima , I. Yiasemi , J. Mavrou , T. Trattonikolas , I. Stylianou , F. Meroueh , E. Murauer , A. Mieuset , R. Ranieri , N. Cocco , V. Busmachiu , I. Barbirosh , L. Tataru , S. Doltu , S. Mazzilli , L. Tavoschi , L. Baglietto
{"title":"Assessing vaccine hesitancy and vaccine literacy among the European prison population and staff: A multicentre observational study","authors":"D. Petri ,&nbsp;M. Fornili ,&nbsp;E. De Vita ,&nbsp;M.A. Malanima ,&nbsp;I. Yiasemi ,&nbsp;J. Mavrou ,&nbsp;T. Trattonikolas ,&nbsp;I. Stylianou ,&nbsp;F. Meroueh ,&nbsp;E. Murauer ,&nbsp;A. Mieuset ,&nbsp;R. Ranieri ,&nbsp;N. Cocco ,&nbsp;V. Busmachiu ,&nbsp;I. Barbirosh ,&nbsp;L. Tataru ,&nbsp;S. Doltu ,&nbsp;S. Mazzilli ,&nbsp;L. Tavoschi ,&nbsp;L. Baglietto","doi":"10.1016/j.jvacx.2024.100537","DOIUrl":"10.1016/j.jvacx.2024.100537","url":null,"abstract":"<div><p>Vaccination is the most efficient and cost-effective public health intervention. Prison population, for its low social distancing, constant turnover, and high percentage of migrants, should be an important target of vaccination campaign. However, vaccination coverage in prison is low. In this study we estimated vaccine hesitancy and vaccine literacy among the prison population and staff and assessed their correlation.</p><p>We conducted a cross-sectional study in 13 prisons of 4 European countries. The sample included 847 people living in prison and 755 staff members. Through a structured questionnaire we assessed vaccine hesitancy, vaccine literacy, general health literacy, previous vaccine refusal and socio-demographic characteristics of participants. Exploratory factor analysis was used to extract three components of vaccine hesitancy. Logistic regression was applied to assess the association between previous vaccine refusal and vaccine hesitancy; linear regression was applied to assess the association between vaccine hesitancy and vaccine and general health literacy. All analyses were adjusted for socio-demographic variables.</p><p>We identified three components of vaccine hesitancy explaining 49% of the total variance: <em>Mistrust</em>, <em>Concern</em> and <em>Conspiracy</em>. In both people living in prison and staff, all the components were associated to previous vaccine refusal (p-value &lt; 0.001) and presented good internal consistency (Cronbach’s alpha = 0.90, 0.73 and 0.78). Young participants presented the highest levels of vaccine hesitancy; migrant people living in prison had the lower levels of <em>Mistrust</em> and the higher level of <em>Concern</em>; all three factors were lower among participants with the highest degree of education. <em>Mistrust</em> and <em>Concern</em> were inversely associated with vaccine literacy while all three subscales were inversely associated with general health literacy (all p-values &lt; 0.001).</p><p>This study suggests that educational interventions aimed at increasing vaccine literacy in people living and working in prison could decrease vaccine hesitation and consequently increase vaccination uptake among the prison population and staff.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"20 ","pages":"Article 100537"},"PeriodicalIF":2.7,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224001104/pdfft?md5=f3434b6dfe20d2ef216e493a273f5d9c&pid=1-s2.0-S2590136224001104-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141842618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of multidose thermotolerant formulations of a vector-based Covid-19 vaccine candidate, NDV-HXP-S in different product formats: Stability and preservative efficacy study 开发基于载体的 Covid-19 候选疫苗 NDV-HXP-S 的不同产品规格的多剂量耐热制剂:稳定性和防腐剂功效研究
IF 2.7
Vaccine: X Pub Date : 2024-07-27 DOI: 10.1016/j.jvacx.2024.100535
Anan Bzami, Changcheng Zhu, Marcus Estrada, Jessica A. White, Manjari Lal
{"title":"Development of multidose thermotolerant formulations of a vector-based Covid-19 vaccine candidate, NDV-HXP-S in different product formats: Stability and preservative efficacy study","authors":"Anan Bzami,&nbsp;Changcheng Zhu,&nbsp;Marcus Estrada,&nbsp;Jessica A. White,&nbsp;Manjari Lal","doi":"10.1016/j.jvacx.2024.100535","DOIUrl":"10.1016/j.jvacx.2024.100535","url":null,"abstract":"<div><p>Current lead coronavirus vaccines require continuous cold or ultra-cold storage from the manufacturing site to the field to maintain protective efficacy. Since cold chain capacity is limited and complex, logistics planning is crucial to limit vaccine wastage.[1] The restrictive storage concerns also make it difficult to share vaccines between public health departments and neighboring states, leading to increased vaccine wastage.[2] A Newcastle Disease Virus (NDV) vector-based severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) vaccine candidate, NDV-HXP-S, offers a cost-effective alternative which aims to improve global access to SARS CoV-2 vaccines.[3] The NDV-HXP-S vaccine candidate can be mass-produced in chicken eggs and has demonstrated efficacy in preclinical studies, as well as acceptable safety and<!--> <!-->potent immunogenicity in clinical studies.[3,4–10] To further advance the NDV-HXP-S vaccine candidate, this manuscript describes work focused on the development of multidose thermotolerant vaccine formulations (i.e., those which would not require continuous extended<!--> <!-->refrigeration), making it convenient to use and store, and simplifying transport and distribution logistics, especially in outbreak settings. Liquid and lyophilized formulations for parenteral administration were rigorously screened for the vaccine formulation’s ability to maintain S-antigen stability after exposure to temperature<!--> <!-->stress at 40 °C, 25 °C, and 2 °C to 8 °C storage for six months. Preservative efficacy was evaluated to enable a multidose liquid vaccine format as well as endotoxin testing in lyophilized formulations. Lead liquid vaccine formations were identified that were able to maintain S-antigen content at 2 °C to 8 °C and 25 °C storage for the entire six-month study. Lead lyophilized vaccine formulations were identified which were able to maintain S-antigen content for six months at 2 °C to 8 °C, 25 °C, and 40 °C. Both the liquid and lyophilized formulations identified are improved thermotolerant SARS-CoV-2 vaccine formulations.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"20 ","pages":"Article 100535"},"PeriodicalIF":2.7,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224001086/pdfft?md5=9c8e3409bd752b317ceaec848e64544b&pid=1-s2.0-S2590136224001086-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141840690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信